NASDAQ:XENE

Xenon Pharmaceuticals News Headlines

$18.51
+0.37 (+2.04 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.71
$18.69
50-Day Range
$16.66
$20.00
52-Week Range
$9.32
$21.94
Volume134,417 shs
Average Volume180,207 shs
Market Capitalization$758.23 million
P/E RatioN/A
Dividend YieldN/A
Beta1.2

Headlines

Xenon Pharmaceuticals (NASDAQ XENE) News Headlines Today

SourceHeadline
Xenon Pharmaceuticals (XENE) to Release Quarterly Earnings on TuesdayXenon Pharmaceuticals (XENE) to Release Quarterly Earnings on Tuesday
americanbankingnews.com - May 5 at 11:13 AM
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2021 Financial Results and Provide Corporate UpdateXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2021 Financial Results and Provide Corporate Update
finance.yahoo.com - May 4 at 8:20 PM
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Up to $18.32Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Up to $18.32
americanbankingnews.com - May 3 at 12:06 PM
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of "Buy" by BrokeragesXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of "Buy" by Brokerages
americanbankingnews.com - April 27 at 4:56 AM
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Expected to Announce Quarterly Sales of $3.70 MillionXenon Pharmaceuticals Inc. (NASDAQ:XENE) Expected to Announce Quarterly Sales of $3.70 Million
americanbankingnews.com - April 27 at 1:34 AM
-$0.45 EPS Expected for Xenon Pharmaceuticals Inc. (NASDAQ:XENE) This Quarter-$0.45 EPS Expected for Xenon Pharmaceuticals Inc. (NASDAQ:XENE) This Quarter
americanbankingnews.com - April 25 at 10:12 PM
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Up 6.4%Xenon Pharmaceuticals (NASDAQ:XENE) Shares Up 6.4%
americanbankingnews.com - April 22 at 3:18 PM
Xenon Pharmaceuticals (NASDAQ:XENE)  Shares Down 3.3% Xenon Pharmaceuticals (NASDAQ:XENE) Shares Down 3.3%
americanbankingnews.com - April 21 at 3:44 PM
Xenon Pharmaceuticals (NASDAQ:XENE) Trading Up 6.8%Xenon Pharmaceuticals (NASDAQ:XENE) Trading Up 6.8%
americanbankingnews.com - April 15 at 1:50 PM
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Up to $18.12Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Up to $18.12
americanbankingnews.com - April 14 at 1:00 PM
How Many Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Do Institutions Own?How Many Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Do Institutions Own?
finance.yahoo.com - April 13 at 6:45 PM
Xenon Pharmaceuticals to Participate in the Stifel 3rd Annual CNS DayXenon Pharmaceuticals to Participate in the Stifel 3rd Annual CNS Day
finance.yahoo.com - March 29 at 7:15 PM
Xenon Pharmaceuticals Announces Closing of $115 Million Public Offering and Full Exercise of the Underwriters Option to Purchase Additional SharesXenon Pharmaceuticals Announces Closing of $115 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
benzinga.com - March 14 at 11:36 PM
Xenon Pharmaceuticals Announces Closing of $115 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesXenon Pharmaceuticals Announces Closing of $115 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - March 12 at 3:40 PM
Xenon Pharmaceuticals Announces Pricing of $100.0 Million Public OfferingXenon Pharmaceuticals Announces Pricing of $100.0 Million Public Offering
finance.yahoo.com - March 10 at 1:21 AM
Xenon Pharmaceuticals Announces Collaboration with Researchers at Icahn School of Medicine at Mount Sinai to Conduct a Phase 2 Study of XEN1101 for the Treatment of Major Depressive Disorder (MDD)Xenon Pharmaceuticals Announces Collaboration with Researchers at Icahn School of Medicine at Mount Sinai to Conduct a Phase 2 Study of XEN1101 for the Treatment of Major Depressive Disorder (MDD)
finance.yahoo.com - March 8 at 6:48 PM
Xenon Pharmaceuticals Reports 2020 Financial Results and Provides Corporate UpdateXenon Pharmaceuticals Reports 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - March 1 at 8:31 PM
Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Tops Revenue EstimatesXenon Pharmaceuticals (XENE) Reports Q4 Loss, Tops Revenue Estimates
finance.yahoo.com - March 1 at 8:31 PM
Xenon Pharmaceuticals Announces Promising New Pre-Clinical Data and Provides Clinical Overview of its XEN1101 Program at ASENT 2021Xenon Pharmaceuticals Announces Promising New Pre-Clinical Data and Provides Clinical Overview of its XEN1101 Program at ASENT 2021
finance.yahoo.com - February 22 at 6:25 PM
If You Had Bought Xenon Pharmaceuticals (NASDAQ:XENE) Shares Three Years Ago Youd Have Earned 316% ReturnsIf You Had Bought Xenon Pharmaceuticals (NASDAQ:XENE) Shares Three Years Ago You'd Have Earned 316% Returns
finance.yahoo.com - February 12 at 5:26 PM
Xenon Pharmaceuticals Outlines Key Milestone Opportunities and Planned Leadership Transition in 2021Xenon Pharmaceuticals Outlines Key Milestone Opportunities and Planned Leadership Transition in 2021
finance.yahoo.com - January 14 at 10:27 AM
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at AES2020, the Virtual Annual Meeting of the American Epilepsy SocietyXenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at AES2020, the Virtual Annual Meeting of the American Epilepsy Society
finance.yahoo.com - December 7 at 6:22 PM
Heres What Analysts Are Forecasting For Xenon Pharmaceuticals Inc. (NASDAQ:XENE) After Its Third-Quarter ResultsHere's What Analysts Are Forecasting For Xenon Pharmaceuticals Inc. (NASDAQ:XENE) After Its Third-Quarter Results
finance.yahoo.com - November 9 at 6:28 PM
Xenon Pharmaceuticals Inc. (XENE) CEO Simon Pimstone on Q3 2020 Results - Earnings Call TranscriptXenon Pharmaceuticals Inc. (XENE) CEO Simon Pimstone on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 8 at 7:43 AM
Xenon Pharmaceuticals Inc (XENE) Q3 2020 Earnings Call TranscriptXenon Pharmaceuticals Inc (XENE) Q3 2020 Earnings Call Transcript
finance.yahoo.com - November 7 at 12:59 AM
These Analysts Think Xenon Pharmaceuticals Inc.s (NASDAQ:XENE) Sales Are Under ThreatThese Analysts Think Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Sales Are Under Threat
nasdaq.com - November 6 at 2:58 PM
Analysts Have Just Cut Their Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Revenue Estimates By 18%Analysts Have Just Cut Their Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Revenue Estimates By 18%
finance.yahoo.com - November 6 at 2:58 PM
Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Lags Revenue EstimatesXenon Pharmaceuticals (XENE) Reports Q3 Loss, Lags Revenue Estimates
finance.yahoo.com - November 6 at 12:09 AM
Xenon Pharma EPS misses by $0.14, misses on revenueXenon Pharma EPS misses by $0.14, misses on revenue
seekingalpha.com - November 5 at 7:09 PM
Xenon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateXenon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - November 5 at 7:09 PM
Xenon Pharmaceuticals: Updates To Thesis, Low Valuation With Multiple Catalysts In 2021Xenon Pharmaceuticals: Updates To Thesis, Low Valuation With Multiple Catalysts In 2021
seekingalpha.com - November 4 at 6:42 PM
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2020 Financial Results and Provide Corporate UpdateXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2020 Financial Results and Provide Corporate Update
finance.yahoo.com - November 2 at 5:56 PM
Xenon Pharmaceuticals Inc. Regi (XP0.SG)Xenon Pharmaceuticals Inc. Regi (XP0.SG)
ca.finance.yahoo.com - October 18 at 5:58 PM
Xenon Pharmaceuticals Receives FDA Feedback and is on Track to Initiate XEN496 Phase 3 Clinical Trial for the Treatment of KCNQ2-DEE Before Year-EndXenon Pharmaceuticals Receives FDA Feedback and is on Track to Initiate XEN496 Phase 3 Clinical Trial for the Treatment of KCNQ2-DEE Before Year-End
markets.businessinsider.com - October 8 at 12:21 PM
Xenon Pharma on go with late-stage study of XEN496 in rare pediatric epilepsyXenon Pharma on go with late-stage study of XEN496 in rare pediatric epilepsy
seekingalpha.com - October 8 at 12:21 PM
We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Easily Afford To Drive Business GrowthWe Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Easily Afford To Drive Business Growth
finance.yahoo.com - September 22 at 6:56 PM
Xenon Pharmaceuticals, Inc. (XENE) CEO Simon Pimstone on Q2 2020 Results - Earnings Call TranscriptXenon Pharmaceuticals, Inc. (XENE) CEO Simon Pimstone on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com - August 9 at 10:40 AM
Xenon Pharmaceuticals (XENE) Reports Break-Even Earnings for Q2Xenon Pharmaceuticals (XENE) Reports Break-Even Earnings for Q2
finance.yahoo.com - August 6 at 11:58 PM
Xenon Pharma EPS beats by $0.24, beats on revenueXenon Pharma EPS beats by $0.24, beats on revenue
seekingalpha.com - August 6 at 6:57 PM
Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateXenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - August 6 at 6:57 PM
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Provide CorporateXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Provide Corporate
www.bloomberg.com - August 1 at 7:05 PM
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Provide Corporate UpdateXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Provide Corporate Update
finance.yahoo.com - July 30 at 7:31 PM
Did Hedge Funds Make The Right Call On Xenon Pharmaceuticals Inc (XENE) ?Did Hedge Funds Make The Right Call On Xenon Pharmaceuticals Inc (XENE) ?
finance.yahoo.com - July 12 at 2:04 PM
Perimeter Medical Imaging: Perimeter Announces Appointment of Ian Mortimer as Director and Stock Option GrantsPerimeter Medical Imaging: Perimeter Announces Appointment of Ian Mortimer as Director and Stock Option Grants
www.finanznachrichten.de - July 3 at 7:08 PM
Perimeter Announces Appointment of Ian Mortimer as Director and Stock Option GrantsPerimeter Announces Appointment of Ian Mortimer as Director and Stock Option Grants
finance.yahoo.com - July 3 at 7:08 PM
Xenon Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare ConferenceXenon Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference
finance.yahoo.com - June 1 at 6:34 PM
News Flash: Analysts Just Made A Sizeable Upgrade To Their Xenon Pharmaceuticals Inc. (NASDAQ:XENE) ForecastsNews Flash: Analysts Just Made A Sizeable Upgrade To Their Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Forecasts
finance.yahoo.com - June 1 at 1:34 PM
Earnings Beat: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsEarnings Beat: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
finance.yahoo.com - May 25 at 9:53 AM
The Xenon Pharmaceuticals (NASDAQ:XENE) Share Price Is Up 247% And Shareholders Are Boasting About ItThe Xenon Pharmaceuticals (NASDAQ:XENE) Share Price Is Up 247% And Shareholders Are Boasting About It
finance.yahoo.com - May 22 at 12:40 PM
Xenon Pharma EPS beats by $0.10, beats on revenueXenon Pharma EPS beats by $0.10, beats on revenue
seekingalpha.com - May 21 at 8:01 PM
This page was last updated on 5/8/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.